Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents.
Related Items
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Last modified: July 22, 2021